NASDAQ:CMMB Chemomab Therapeutics Q1 2026 Earnings Report $1.81 +0.04 (+2.26%) Closing price 03:59 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Chemomab Therapeutics EPS ResultsActual EPS-$0.22Consensus EPS -$0.04Beat/MissMissed by -$0.18One Year Ago EPSN/AChemomab Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AChemomab Therapeutics Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time8:00AM ETUpcoming EarningsChemomab Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Chemomab Therapeutics Earnings HeadlinesChemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 4.7% - Here's What HappenedJune 5 at 2:23 AM | americanbankingnews.comChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate UpdateMay 14, 2026 | globenewswire.comThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the world's largest fund managers - including a section naming one small company Musk's Colossus cannot operate without. Right now, most fund managers have never heard of it. By Friday, every one of them will. Dylan Jovine has identified the name and ticker before $75 billion in new capital starts chasing the SpaceX supply chain.June 8 at 1:00 AM | Behind the Markets (Ad)Chemomab Therapeutics Ltd ADR CMMBMay 8, 2026 | morningstar.comMChemomab Therapeutics - Depositary Receipt (CMMB) price target decreased by 14.29% to 15.30March 28, 2026 | msn.comChemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate UpdateMarch 19, 2026 | globenewswire.comSee More Chemomab Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chemomab Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chemomab Therapeutics and other key companies, straight to your email. Email Address About Chemomab TherapeuticsChemomab Therapeutics (NASDAQ:CMMB) (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development. Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade. Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.View Chemomab Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?Planet Labs: Coming Back Down to EarthDocusign: Another Beat, Another Selloff—Why the Analysts Are WrongA Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowWhat's Make of Macy's: Berkshire Hathaway's Latest BuyA Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
